Merrimack Pharmaceuticals Announces Timing of Second

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Merrimack Pharmaceuticals Announces Timing of Second Quarter 2013 Investor Conference Call

CAMBRIDGE, Mass., July 25, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) today announced that the company will host its Second Quarter 2013 Investor Conference Call and webcast at 11 a.m., Eastern time, on Thursday, August 8.

The call will cover an update on Merrimack's progress as well as a summary of second quarter financials. A press release detailing the information to be discussed on the call will be issued on the morning of Thursday, August 8.

Investors and the general public are invited to listen to the call by dialing (877) 564-1301 (domestic) or (224) 357-2394 (international) five minutes prior to the start of the call and providing the passcode 23772480.

A listen-only webcast of the call can be accessed in the Investors section of Merrimack's website, http://investors.merrimackpharma.com , and a replay of the call will be archived there for six weeks.

About Merrimack

Merrimack Pharmaceuticals is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research throughout the research and development process. Merrimack currently has six oncology therapeutics in clinical development.

Forward-looking statements

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

Investor Contact: Geoffrey M. Grande, CFA Investor Relations Merrimack Pharmaceuticals 617-441-7602 Media Contact: Dana Robie Corporate Communications Merrimack Pharmaceuticals 617-441-7408

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Arch Biopartners Secures Funding Through Private Placement

Updated Category News Views 147

Arch Biopartners Announces Private Placement to Enhance Growth Arch Biopartners Inc. is excited to share that it has successfully arranged a non-brokered private placement. This offering consists of 225,806 common shares priced at $1.55 each, aiming to raise gross proceeds of $350,000 CAD. This strategic move positions Arch to bolster its working capital, which is...

Continue Reading
Revolutionizing Laboratory Automation: Trilobio's New Platform

Updated Category News Views 376

Trilobio Unveils Comprehensive Lab Automation Platform At the forefront of advancing biology research, Trilobio has introduced a groundbreaking whole lab automation platform at a major conference. This innovative platform integrates robotics, lab equipment, and software, creating a streamlined solution for researchers facing workflow challenges. Transforming Genetic...

Continue Reading
Shell Expands Share Buyback Program with Recent Purchases

Updated Category News Views 61

Shell's Strategic Share Buyback Initiative Shell plc recently announced a significant purchase of shares for cancellation, reaffirming its dedication to enhancing shareholder value. On a specific date, the company acquired a substantial number of shares, a move that is part of the broader share buyback program that was outlined in detail previously. Details of Share...

Continue Reading
Constellium SE to Host Earnings Call for Q3 2024 Results

Updated Category News Views 44

Constellium SE to Share Q3 2024 Financial Update Constellium SE (NYSE: CSTM) is preparing to reveal its third-quarter 2024 results during a special conference call and webcast. This event will occur on a Wednesday morning, aiming to keep stakeholders informed and engaged with the company's latest developments. Details of the Upcoming Conference Call The conference call is...

Continue Reading
Streamline Health Strengthens Partnership with New Contract

Updated Category News Views 133

Expanding Horizons: Streamline Health’s New Contract Streamline Health Solutions, Inc. (NASDAQ: STRM) has recently announced a notable contract for its RevID technology with a health system based in Kentucky. This particular system is a 120-bed facility that utilizes Oracle Health's EHR, marking a significant step in Streamline Health's expansion within the healthcare...

Continue Reading